KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $30,687.50 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now directly owns 100,334 shares of the company’s stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Up 9.5 %

KALV stock opened at $10.71 on Thursday. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The firm has a market cap of $529.27 million, a P/E ratio of -2.94 and a beta of 0.85. The company’s 50-day simple moving average is $8.80 and its 200-day simple moving average is $10.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. lifted its stake in KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after buying an additional 1,200,000 shares in the last quarter. Woodline Partners LP raised its holdings in shares of KalVista Pharmaceuticals by 111.8% during the fourth quarter. Woodline Partners LP now owns 1,288,401 shares of the specialty pharmaceutical company’s stock valued at $10,913,000 after acquiring an additional 680,148 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of KalVista Pharmaceuticals by 19.3% in the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after acquiring an additional 770,000 shares in the last quarter. Tang Capital Management LLC boosted its stake in shares of KalVista Pharmaceuticals by 13.2% in the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock worth $41,451,000 after acquiring an additional 572,300 shares during the last quarter. Finally, Stempoint Capital LP purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $8,409,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on KALV. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).